In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Profiles of COURAGE: Another Speed Bump for Stents or Flawed Trial?

Executive Summary

Cardiologists and interventionalists continue to disagree on the importance of the COURAGE trial results. Academic disputes aside, the question for industry is whether this study will further drive down stent usage.

You may also be interested in...

Another Call for Better Risk Stratification in Cardiac Imaging

New data showing that the slightly more than one-third of patients with previously unconfirmed coronary artery disease who go to the cath lab for invasive angiography testing actually have an obstructive blockage are sure to ratchet up the already active discussions around the appropriate use of cardiac imaging - both from the effectiveness and safety perspectives. Part of the solution may be the development of molecular IVD tests aimed at triaging patients to imaging. Even if slow to integrate this brand of R&D into their development strategies, some makers of in vivo imaging equipment are beginning to realize this.

CardioDx: Bringing Molecular Diagnostics Into the Cardiovascular Arena

Buoyed by their success with Genomic Health, a trio of West Coast VCs have expanded their portfolios of molecular diagnostic companies, with many following similar themes. CardioDx has developed a test to distinguish between patients who should move on to cardiac imaging and those they are comfortable managing otherwise. Such a rule-out test is a challenging proposition. But if adopted, and more broadly, as molecular diagnostics move into new and broad markets like cardiology and metabolic disease, pharma could use this opportunity to its advantage in many settings, including co-marketing arrangements.

Top Device Stories of the Decade

A look back at the biggest devices stories of the decade, in capsule form.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts